Search by Drug Name or NDC

    NDC 63323-0122-50 Methotrexate 1 g/1 Details

    Methotrexate 1 g/1

    Methotrexate is a INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Fresenius Kabi USA, LLC. The primary component is METHOTREXATE SODIUM.

    Product Information

    NDC 63323-0122
    Product ID 63323-122_10ac151e-e0da-4686-b2a1-c706982e777a
    Associated GPIs 21300050102150
    GCN Sequence Number 008790
    GCN Sequence Number Description methotrexate sodium/PF VIAL 1 G INJECTION
    HIC3 V1B
    HIC3 Description ANTINEOPLASTIC - ANTIMETABOLITES
    GCN 38468
    HICL Sequence Number 024819
    HICL Sequence Number Description METHOTREXATE SODIUM/PF
    Brand/Generic Generic
    Proprietary Name Methotrexate
    Proprietary Name Suffix n/a
    Non-Proprietary Name METHOTREXATE SODIUM
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
    Route INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS
    Active Ingredient Strength 1
    Active Ingredient Units g/1
    Substance Name METHOTREXATE SODIUM
    Labeler Name Fresenius Kabi USA, LLC
    Pharmaceutical Class Folate Analog Metabolic Inhibitor [EPC], Folic Acid Metabolism Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA040266
    Listing Certified Through 2024-12-31

    Package

    NDC 63323-0122-50 (63323012250)

    NDC Package Code 63323-122-50
    Billing NDC 63323012250
    Package 1 VIAL in 1 CARTON (63323-122-50) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL
    Marketing Start Date 2000-01-22
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL ec476b11-0b3c-4139-b1eb-a3daa76bc271 Details

    Revised: 3/2021